Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
OMER logo OMER
Upturn stock ratingUpturn stock rating
OMER logo

Omeros Corporation (OMER)

Upturn stock ratingUpturn stock rating
$3.08
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/02/2025: OMER (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

4 Analysts rated it

These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.

Year Target Price $22.5

Year Target Price $22.5

Analyst’s Price TargetsFor last 52 week
$22.5Target price
Low$2.97
Current$3.08
high$13.6

Analysis of Past Performance

Type Stock
Historic Profit 40.3%
Avg. Invested days 29
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 3.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/02/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 187.50M USD
Price to earnings Ratio -
1Y Target Price 22.5
Price to earnings Ratio -
1Y Target Price 22.5
Volume (30-day avg) -
Beta 2.2
52 Weeks Range 2.97 - 13.60
Updated Date 06/29/2025
52 Weeks Range 2.97 - 13.60
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.04

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -30.7%
Return on Equity (TTM) -576.33%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 337798827
Price to Sales(TTM) 4.93
Enterprise Value 337798827
Price to Sales(TTM) 4.93
Enterprise Value to Revenue 8.26
Enterprise Value to EBITDA -1.49
Shares Outstanding 58592700
Shares Floating 56016786
Shares Outstanding 58592700
Shares Floating 56016786
Percent Insiders 4.4
Percent Institutions 47.39

Analyst Ratings

Rating 3.75
Target Price 22.5
Buy 1
Strong Buy 1
Buy 1
Strong Buy 1
Hold 2
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Omeros Corporation

stock logo

Company Overview

overview logo History and Background

Omeros Corporation, founded in 1994, is a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, and disorders of the central nervous system. It has evolved from early-stage research to a commercial-stage company with FDA-approved products.

business area logo Core Business Areas

  • Complement-Mediated Diseases: Development of therapies targeting the complement system, a part of the immune system, to treat diseases where complement activation plays a role.
  • Central Nervous System Disorders: Development of drugs for CNS disorders, including substance use disorders.

leadership logo Leadership and Structure

Gregory A. Demopulos, M.D. is the Chairman, President, and Chief Executive Officer. The company has a typical corporate structure with various departments including research, development, clinical, commercial, and administrative functions.

Top Products and Market Share

overview logo Key Offerings

  • Omeros Corporation: Omeros Corporation's sole product is called OMIDRIA for intraocular irrigating solutions, which is used during cataract surgery to maintain pupil dilation, and can be used to reduce post-operative pain. No reliable market share figures are publicly available.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is highly competitive and research-intensive, focusing on the development of novel therapies for various diseases. It is subject to strict regulatory oversight and requires significant investment in research and development. Government Regulations include FDA, anti-trust, and safety rules. Reimbursement and pricing pressures from health insurers are also high.

Positioning

Omeros is a commercial-stage biopharmaceutical company, they are specialized in complement and G-protein-coupled receptor (GPCR) platforms. Their product focuses on intraocular irrigating solution.

Total Addressable Market (TAM)

The total addressable market for Omeros' therapeutic areas is significant, spanning across complement-mediated diseases and CNS disorders. Omeros's market position for OMIDRIA in cataract surgery is uncertain due to its sole product and lack of disclosed market share.

Upturn SWOT Analysis

Strengths

  • Proprietary technology platforms
  • FDA-approved product (OMIDRIA)
  • Experienced management team
  • Targeting large and unmet medical needs

Weaknesses

  • Reliance on a single product
  • History of financial losses
  • Dependence on successful clinical trials for pipeline products
  • Competitive landscape

Opportunities

  • Expansion of OMIDRIA's market reach
  • Advancement of pipeline candidates through clinical trials
  • Potential partnerships and collaborations
  • Acquisition of complementary technologies or products

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles and delays
  • Unfavorable reimbursement policies
  • Patent challenges and litigation

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • ALC
  • VTVT

Competitive Landscape

Omeros faces intense competition from established pharmaceutical companies with greater resources. Its success depends on differentiating its products and successfully navigating the regulatory landscape.

Growth Trajectory and Initiatives

Historical Growth: Omeros's historical growth has been uneven, largely dependent on OMIDRIA sales and the success of its clinical development programs.

Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercialization of pipeline candidates. Analyst estimates vary widely due to the inherent uncertainty in biopharmaceutical development.

Recent Initiatives: Recent initiatives include advancing its pipeline candidates through clinical trials, seeking regulatory approvals, and exploring potential partnerships.

Summary

Omeros is a biopharmaceutical company with a single FDA-approved product and a pipeline of drug candidates. Its future depends on the successful development and commercialization of its pipeline products. The company's financial performance has been volatile, and it faces significant competition. The company needs to successfully manage it's debt and cash flow while it works to grow its sales and obtain regulatory approvals for its products.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company filings
  • Analyst reports
  • Publicly available information

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Omeros Corporation

Exchange NASDAQ
Headquaters Seattle, WA, United States
IPO Launch date 2009-10-08
Co-Founder, Chairman, CEO & President Dr. Gregory A. Demopulos M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 202
Full time employees 202

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.